The abstract is read at the publisher; the summary is JClub's.
Intravenous AAV9-ASAH1 gene therapy in symptomatic P361R-Farber (Asah1 P361R/P361R) mice prolonged lifespan and corrected peripheral and central nervous system pathology in a dose-dependent manner.
- Why it matters: Acid ceramidase deficiency from ASAH1 mutations causes Farber disease and SMA-PME, fatal lysosomal storage disorders with ceramide accumulation and no curative treatment.
- What they did: Symptomatic P361R-Farber mice received an escalating intravenous dose of recombinant AAV9 expressing human ASAH1, then were assessed for 6 months using clinical, molecular, and histological readouts.
- The result: The approach is proof-of-concept that systemic AAV-mediated gene therapy may be a therapeutic option for patients with acid ceramidase deficiency.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.